# Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

> **NCT00184548** · PHASE3 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 554 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Trauma

## Interventions

- **DRUG:** eptacog alfa (activated)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00184548
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 554 (ACTUAL)
- **Why stopped:** See termination reason in detailed description
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184548, "Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00184548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*